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Abstract
Background: Cell-penetrating peptides (CPPs) have been widely used as carriers to transport different molecules
into living cells, whereas messenger RNAs (mRNAs) have been utilized as target molecules for the prevention and
treatment of various diseases. However, the instability of CPPs and mRNAs has limited their application.
Bacteriophage PP7 virus-like particles (VLPs) may protect peptides and RNAs from degradation through displaying
foreign peptides on their surface and encapsidating RNA linked with the pac site.
Results: In this study, the cDNA of the PP7 coat protein single-chain dimer carrying low molecular weight
protamine (LMWP) and the cDNA of green fluorescent protein (GFP) were inserted into two multiple cloning sites
of pETDuet-1, respectively. PP7 VLPs carrying the LMWP peptide and GFP mRNA were subsequently expressed in
Escherichia coli BL21 (DE3) with high yield and thermal stability, and were easily purified. The VLPs were also
non-replicative, non-infectious, and non-toxic. Moreover, they penetrated the mouse prostate cancer cells RM-1
after 24 h incubation. Last, PP7 VLPs carrying the LMWP could encapsidate the GFP mRNA, which was translated
into mature protein in mammalian cells.
Conclusions: Recombinant PP7 VLPs can be used simultaneously as a targeted delivery vector for both peptides
and mRNA due to their abilities to package RNA and display peptides.
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Background
Cell-penetrating peptides (CPPs) are short positively
charged peptides containing less than 30 amino acid
residues. They exhibit low toxicity and have the cap-
acity to cross cellular membranes by energy-dependent
and/or independent mechanisms [1, 2]. In the process,
CPPs can transport different molecules such as nano-
particles [3], liposomes [4], proteins [5], peptides [5],
and oligonucleotides [5–7] into living cells. Different
delivery strategies such as direct conjugation, co-
incubation, and non-covalent or covalent cross-linking
of CPPs with target molecules [4–9] have been investi-
gated so far.
Several factors currently limit the preclinical and clin-
ical development of CPPs. Fist, CPPs require custom
synthesis, are expensive, and can be easily degraded by
intracellular or extracellular proteases [10]. Second, the
crosslinking efficiency of CPPs with target molecules is
low [11]. Therefore, a simple, safe, effective, stable, and
cost-effective delivery vehicle for CPPs is needed to im-
prove their stability and utilization efficiency.
Bacteriophage PP7 virus-like particles (VLPs) may be a
promising tool in meeting the above requirements as a
CPP delivery vehicle because PP7 VLPs can be expressed
in Escherichia coli (E. coli) strains such as CSH41F [12].
Additionally, the PP7 coat protein has the ability to self-
assemble into VLPs in the absence of viral RNA, and
these VLPs in turn can serve as a vector for peptides
[12, 13]. Specifically, in the viral capsid, the β-hairpin
structures at the N terminus of the coat protein subunits
protruding from the surface of PP7 VLPs can tolerate
foreign peptides [12]. These peptides can be inserted be-
tween amino acid residues 10 and 11 of the second sub-
unit of the coat protein single-chain dimer [12]. The
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insertion of DNA oligonucleotides at this site allows the
production of chimeric PP7 coat proteins that have the
foreign peptide placed in the central part of the hairpin.
Most importantly, the displayed peptides are highly im-
munogenic [14]. Furthermore, the PP7 VLPs with the
inserted peptides are heat-resistant up to about 70 °C
and are therefore more stable than MS2 VLPs that resist
heat up to 50 °C [15].
To date, the PP7 VLPs have been used as peptide vac-
cine carriers against the human papillomavirus [16] and
malaria parasite [17]. However, whether CPPs can also
be successfully displayed on the surface of PP7 VLPs
and additionally retain their cell-penetrating function
have not been examined yet. It is also known that PP7
VLPs encapsidate coat protein-specific messenger RNA
(mRNA) [12]; however, whether they can encapsidate
foreign mRNA has not been investigated either. There-
fore, in this study, we have chosen the low molecular
weight protamine (LMWP) (VSRRRRRRGGRRRR) pep-
tide as the model CPP and analyzed the expression of
PP7 VLPs carrying the LMWP in E. coli strain BL21
(DE3). We also evaluated the cell-penetrating ability of
the inserted LMWP and analyzed whether PP7 VLPs
could package the foreign mRNA.
Results
Insertion of the LMWP peptide into the PP7 coat protein
dimer
The expression vector of PP7 VLPs carrying the LMWP
peptide was constructed as follows: the 771-bp coding
sequence of 2PP7 with one introduced restriction enzyme
site KpnI (Fig. 1a) was first inserted between the NdeI and
XhoI restriction sites of the prokaryotic expression vector
pETDuet-1. The obtained vector was named pETduet-
2PP7; it encodes for a 27.944 kDa protein with 256 amino
acid residues. The cDNA of LMWP was then inserted
after the KpnI site (Fig. 1a), which is located in the second
AB-loop of the PP7 coat protein and can tolerates peptide
insertions [12]. The resulting constructed vector was
named pETDuet-2PP7-Protamine. All positive clones
were screened by colony PCR and verified by sequencing.
To predict whether the PP7 coat protein could tolerate
the insertion of LMWP peptide, the program RasMol
2.7.1 was used. The results showed the PP7 coat protein
could indeed tolerate the insertion of the LMWP pep-
tide. The secondary structure of LMWP after having
been inserted in the PP7 coat protein was mainly β-
sheet and β-turn (Fig. 1b).
Last, the plasmid pETDuet-2PP7-Protamine-GFP was
constructed by inserting the GFP gene between the XbaI
and BamHI restriction sites of the plasmid pETDuet-
2PP7-Protamine. The correct construct was also verified
by sequencing.
Expression of recombinant 2PP7-Protamine-GFP VLPs in
E. coli
To analyze the expression of PP7 VLPs carrying the peptide
or not carrying the peptide, the three recombinant expres-
sion vectors above were transformed into E. coli. The
results showed three recombinant VLPs: 2PP7 VLPs, 2PP7-
Fig. 1 Insertion of the LMWP peptide into the PP7 coat protein dimer. The cDNA sequence of LMWP (in red) was inserted after the KpnI site of the
vector pETDuet-2PP7 (a). The possible structure of the PP7 coat protein dimer carrying LMWP with the AB-loops shown in ribbon was predicted using
the program RasMol 2.7.1 (b)
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Protamine VLPs, and 2PP7-Protamine-GFP, each expressed
intracellularly from the plasmids pETDuet-2PP7, pETDuet-
2PP7-Protamine, and pETDuet-2PP7-Protamine-GFP re-
spectively. The above VLPs represented a dominant protein
species in the supernatant of lysed bacteria after centrifuga-
tion (Fig. 2a). Furthermore, 2PP7 coat protein, 2PP7-
Protamine coat protein, and 2PP7-Protamine-GFP coat
protein were found in the precipitate, but whether these
could fold into VLPs was not determined. SDS-PAGE ana-
lysis revealed that the molecular weight of the single-chain
dimer of PP7 phage coat protein carrying the LMWP or
not carrying the LMWP was approximately 33 kDa, and
the latter was smaller than the former (Fig. 2a).
The VLPs were then purified by size-exclusion chroma-
tography (Fig. 2b). The western blotting results showed
the VLPs existed in the first elution peak (Figs. 2b and 3a),
and the expression levels of the purified 2PP7 VLPs,
2PP7-Protamine VLPs, and 2PP7-Protamine-GFP VLPs
extracted from the supernatant of 1 L of overnight culture
after sonication were approximately 5.56, 2.42, and
1.45 mg/L, respectively. These results demonstrated that
PP7 VLPs carrying LMWP or not carrying LMWP could
be expressed in E. coli BL21 (DE3) with high-efficiency;
however, the fusion of the peptide to PP7 coat protein and
the inserted GFP gene in the second multiple cloning sites
(MCSs) of the plasmid pETDuet-2PP7-Protamine de-
creased the expression of the PP7 VLPs.
Assembly of the PP7 coat protein dimer carrying the
LMWP peptide into whole VLPs
To confirm that the purified products successfully as-
sembled into PP7 VLPs, western blotting and TEM were
performed. The western blotting results showed only
one specific band appearing in every lane, which demon-
strated that all three recombinant VLPs could be de-
tected by the murine antibody of the anti-coat protein of
Fig. 2 Expression of recombinant 2PP7-Protamine-GFP VLPs in E. coli. a Expression of 2PP7-Protamine and 2PP7-Protamine-GFP VLPs in the supernatant
of BL21 (DE3) after sonication. Lanes of BL21 (DE3) carrying each plasmid are designated as follows: lane 1, plasmid pETDuet-2PP7-Protamine-GFP with
IPTG added; lane 2, plasmid pETDuet-2PP7-Protamine without IPTG added; lane 3, pETDuet-2PP7-Protamine without IPTG added; lane 4, pETDuet-2PP7-
Protamine with IPTG added; lane 5, pETDuet-2PP7 with IPTG added. b-d Purification of the VLPs. The peaks of the target proteins are marked by red arrows
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PP7 phage (Fig. 3a). In addition, the TEM results indi-
cated that the recombinant PP7 capsids could assemble
into the whole virus-like particles with a diameter of
about 30 nm (Fig. 3b-d), which was similar to that of
wild-type PP7 VLPs.
Packaging and protection from degradation of the RNA
linked with PP7 pac site by the recombinant PP7 VLPs
carrying the LMWP peptide
The chromatogram showed nucleic acid was present
in the first peak, indicating that nucleic acids were
packaged by the PP7 VLPs (Fig. 2b). To verify this re-
sult and examine the type of nucleic acid (DNA or
RNA) that was packaged by the PP7 VLPs, a nuclease-
resistance assay and RT-PCR were performed. Results
from the nuclease-resistance assay showed that, after
incubation of 2PP7 VLPs, 2PP7-Protamine VLPs, and
2PP7-Protamine-GFP VLPs with DNase I and RNase
A, a band was observed in each lane but at different
locations (Fig. 4a). These results showed that nucleic
acids with different characteristics in terms of lengths
and folding degrees were packaged by the PP7 VLPs.
Following the above assay, the DNAs or RNAs pack-
aged by these VLPs were further verified by RT-PCR.
The results showed that the RNA and not DNA was the
nucleic acid packaged by these VLPs (Fig. 4b). Moreover,
the RNAs most likely packaged by the 2PP7-Protamine
VLPs and 2PP7-Protamine-GFP VLPs were the mRNAs
of PP7 coat protein carrying LMWP and GFP (Fig. 4b).
The results indicated that the PP7 VLPs carrying LMWP
retained the ability to package mRNA and therefore
could be used as a delivery vector of mRNA.
Cytotoxicity and thermal stability of 2PP7-Protamine and
2PP7-Protamine-GFP VLPs
The cytotoxicity of 2PP7, 2PP7-Protamine, and 2PP7-
Protamine-GFP VLPs was examined in the African green
monkey kidney fibroblast cell line Cos-7 using CCK-8
assay. The results showed no dose-dependent cytotoxicity
in these three VLPs (Fig. 5a-c). Even at a high concentra-
tion of 800 μg/mL of VLPs, cell viability was higher than
95 %, demonstrating low cytotoxicity of recombinant
2PP7, 2PP7-Protamine, and 2PP7-Protamine-GFP VLPs.
At the same time, the thermal stability of these three
VLPs was determined by measuring the protein concen-
tration at different temperatures. The results showed
that the concentrations of 2PP7, 2PP7-Protamine and
2PP7-Protamine-GFP VLPs decreased significantly at
above 60 °C (P < 0.01, Fig. 5d), indicating that they
resisted heating up to about 60 °C. Additionally, the sta-
bility of these three VLPs was identical at the same
temperature (Fig. 5d). The results showed the high ther-
mal stability of the PP7 VLPs carrying LMWP and of
those not carrying LMWP.
Cell-penetrating ability of PP7 VLPs carrying the LMWP
peptide
To explore whether recombinant PP7 VLPs carrying
LMWP can penetrate cells, the 2PP7-Protamine VLPs
were labeled with fluorescein isothiocyanate (FITC) and
incubated with cells from the mouse prostate cancer cell
Fig. 3 Recognition and assembly of the PP7coat protein dimer carrying LMWP into whole VLPs. a Western blot of VPLs: lane 1, TBS; lane 2, 2PP7
VLPs; lane 3, 2PP7-Protamine VLPs; lane 4, 2PP7-Protamine-GFP VLPs; Lane 5, BL21 (DE3) carrying pETDuet-1 induced by IPTG. b-d VLPs observed
using TEM at 60 kV and 100,000× screen magnification
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line RM-1. After 12 h, the RM-1 cells incubated with
2PP7-Protamine VLPs exhibited a high level of fluores-
cence (Fig. 6). In contrast, no fluorescence could be
detected in the cells incubated with unlabeled 2PP7-
Protamine VLPs or FITC-labeled 2PP7 VLPs (Fig. 6).
These results indicate that the LMWP was expressed on
the surface of 2PP7-Protamine VLPs and that these VLPs
retained strong cell-penetrating ability. Therefore, we
conclude that display of other targeting cell-penetrating
peptides on the surface of PP7 VLPs will be possible.
The strong cell-penetrating ability of the PP7 VLPs may
enhance the in vivo delivery efficiency of RNA and lay
the foundation for targeted delivery of RNA.
Protein translation of the mRNA packaged by PP7 VLPs
carrying the LMWP peptide
We investigated whether the GFP mRNA packaged by
the PP7 capsid carrying the LMWP peptide could be
translated into mature protein in RM-1 cells. After
24 h of incubation with 2PP7-Protamine-GFP VLPs,
most of the RM-1 cells incubated with 2PP7-
Protamine-GFP VLPs exhibited green fluorescence
(Fig. 7a), which was identified by the confocal laser
scanning microscopy. As shown in Fig. 7b, green
fluorescence was observed in the cytoplasm of almost
all RM-1 cells, while red fluorescence from red fluor-
escent reactive dye was observed on the membrane of
RM-1 cells and blue fluorescence from DAPI inside
the nuclei.
Additionally, the levels of GFP mRNA level in the
RM-1 cells were verified by quantitative real-time PCR
(qPCR) at 24 h and 48 h (Fig. 7c). As shown in Fig. 7c,
whether at 24 h or at 48 h, the GFP mRNA could not be
detected in the cells incubated with 2PP7-Protamine
VLPs. Instead, the higher level of GFP mRNA was ob-
served in thecells incubated with 2PP7-Protamine-GFP
VLPs (P < 0.001). Moreover, in this group, the level of
GFP mRNA at 48 h was significantly higher than that at
24 h. All these results showed that PP7 VLPs carrying
the LMWP peptide could penetrate cell membrane and
that the mRNA packaged by them was translated into
mature protein in mammalian cells.
Fig. 4 Nuclease-resistance assay of mRNA packaged by the PP7 capsid carrying LMWP. a The purified 2PP7 VLPs, 2PP7-Protamine VLPs and
2PP7-Protamine-GFP VLPs (800 μg/ml) were separately mixed with DNase I (20 U/mL) and RNase A (10 mg/mL), incubated at 37 °C for 12 h,
and verified by 1 % agarose gel electrophoresis: lane M, DL 2000 DNA marker; lane 1, 2PP7-Protamine VLPs; lane 2, 2PP7-Protamine-GFP
VLPs; lane 3, 2PP7 VLPs. b Verification of nucleic acids packaged by 2PP7-Protamine VLPs (lanes 1, 2, 3, 4; the PP7 coat protein dimer gene
containing LMWP was amplified) and 2PP7-Protamine-GFP VLPs (lanes 6, 7, 8, 9; the GFP gene was amplified). The PCR products in different
lanes were as follows: lanes 1 and 9, reverse transcription product of RNA extracted from corresponding VLPs; lanes 2 and 8, RNA extracted
from corresponding VLPs; lanes 3 and 7, purified VLP sample; lanes 4 and 6, reverse transcription product of purified VLPs sample; lane 5,
ddH2O. M1, DL 2000 DNA marker; M2, DL 10000 DNA marker
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Discussion
Molecules such as mRNAs have been used for the preven-
tion and treatment of various diseases [18–21], including
cancer [18–20]. However, there are several obstacles in the
in vivo application of mRNAs, including the low in vivo
delivery efficiency of mRNA, their lack of cell-type specifi-
city, and instability. In this study, we introduced a delivery
system based on PP7 VLPs and a cell-penetrating peptide
as a solution to the above limitations of mRNA-targeted
delivery.
In order to improve the delivery efficiency of
mRNA, the PP7 VLPs were decorated with a non-
toxic cell-penetrating peptide, LMWP. This peptide,
similar to the peptide TAT, enhanced the intracellu-
lar delivery of the linked particles without any de-
pendence on receptors, temperature conditions, or
energy use and without causing any alterations to
the cell membrane [22–24]. The cell-penetrating
assay showed that the LMWP peptide was displayed
on the surface of PP7 VLPs.
Previous studies have shown that MS2 capsids specific-
ally encapsidate specific mRNAs that are linked to the
MS2 pac site [25–27], and our results showed PP7 capsids
could also do this. As was expected, we found that PP7
VLPs carrying the cell-penetrating peptide LMWP pack-
aged a specific mRNA linked with the pac site and pro-
tected the RNA from rapid extracellular degradation by
RNase. Furthermore, the PP7 VLPs carrying the cell-
penetrating peptide LMWP and GFP mRNA efficiently
penetrated the cell membrane. To date, the greatest length
of RNA packaged using one wild-type pac site in MS2
VLPs fused with a peptide was 970 bases [28]; the length
of the RNA using the PP7 VLPs was 720 bases. However,
it has not been determined whether more than one kind
of RNA was packaged by the PP7 VLPs during their ex-
pression in E. coli. The size and characteristics of the for-
eign RNA that were packaged by the peptide fused to the
PP7 coat protein will therefore need to be studied further.
In addition, the mRNA packaged by the PP7 VLPs
showed a high level of protein expression in mammalian
Fig. 5 Cytotoxicity and thermal stability of 2PP7-Protamine and 2PP7-Protamine-GFP VLPs. 2PP7-Protamine and 2PP7-Protamine-GFP VLPs show
low cytotoxicity in Cos-7 cells (a-c) and high thermal stability at different temperatures (d). The cytotoxicity has been expressed in terms of
cell viability
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Fig. 7 Translation of the mRNA packaged by PP7 VLPs carrying the LMWP peptide. The expression of GFP in the RM-1 cells incubated with 2PP7-
Protamine VLPs or 2PP7-Protamine-GFP VLPs was observed by fluorescence microscopy (a) or confocal laser scanning microscopy (b). The levels
of GFP mRNA in the cells was verified by qPCR (c)
Fig. 6 Cell-penetrating ability of PP7 VLPs carrying the LMWP peptide. Strong cell-penetrating ability was observed. Pictures were taken under
white light or fluorescence (200×)
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cells within 24 h. This result was not in accordance with
that observed for the naked mRNA vaccine, which
showed maximum expression within 12–18 h [29, 30].
This finding underscores the high stability of PP7 VLPs
carrying the LMWP peptide.
In 2011, Caldeira and Peabody proved that PP7 VLPs
with a peptide insertion were generally stable up to
about 70 °C [15]. In this study, the PP7 VLPs carrying
the cell-penetrating peptide LMWP and the GFP mRNA
showed similar thermal stability up to about 60 °C as
those carrying other peptides and, in addition, were
more stable than the MS2 VLPs with peptide insertion.
In summary, our current study demonstrates that PP7
VLPs carrying a cell-penetrating peptide and mRNA can
be expressed in E. coli with high efficiency, are easily
purified, and are nuclease-resistant, non-replicative, non-
toxic, and noninfectious.
Conclusions
The current study provides a stable and efficient mRNA
delivery system that is based on the inherent abilities of
PP7 VLPs to encapsidate mRNA and tolerate foreign
peptides. Moreover, the recombinant PP7 VLPs carrying
the CPP and mRNA can be easily expressed in a pro-
karyotic expression system at high yield, are nuclease-
resistant, non-replicative, nontoxic, and non-infectious.
In addition, the mRNA packaged by these VLPs showed
a high level of protein expression in mammalian cells. In
conclusion, this system holds great potential in the de-
velopment of mRNA and peptide-based targeted thera-
peutics to be used for the prevention and treatment of
cancer and other diseases.
Methods
Plasmid construction
The single-chain dimer gene of PP7 phage coat protein (ac-
cession number: NC_001628.1) with one KpnI site was
amplified by the overlap extension PCR, and inserted into
restriction enzyme sites NdeI and XhoI of the vector
pETDuet-1 (Novagen, Nottingham, UK). This constructed
plasmid was named as pETDuet-2PP7, which was finally
verified by sequencing analysis (Genscript, Nanjing, China).
The plasmid pETDuet-2PP7-Protamine was constructed
based on the plasmid pETDuet-2PP7. Briefly, the gene
containing LMWP was amplified by PCR using primers
2PP7-Protamine-for and PP7-r (Table 1), digested by two
restriction enzymes KpnI and XhoI (Takara, Dalian, China),
and ligated with the plasmid pETDuet-2PP7. After that,
the plasmid pETDuet-2PP7-Protamine-GFP was con-
structed with GFP DNA (accession number: NC_025025.1)
inserted between XbaI and BamHI of the plasmid
pETDuet-2PP7-Protamine. The correct construct was veri-
fied by sequencing analysis. The sequence of all primers
are listed in Table 1.
Protein expression and purification
The plasmids mentioned above were isolated from 2 mL
overnight cultures of single colonies using a QIAprep
Spin Plasmid Kit (Qiagen) and separately transformed
into the competent BL21 (DE3) cells. The transformed
cells were cultured in 5 ml of LB medium supplemented
with ampicillin (50 mg/L). The precultures were used to
inoculate 500 mL of LB medium supplemented with
ampicillin. When these cultures were grown to an
OD600 of approximately 0.6 at 37 °C, isopropyl thio-β-D-
galactoside (IPTG) was added with a final concentration
of 1 mM and these cultures were incubated overnight at
37 °C. The cells were harvested using centrifugation at
12,000 rpm for 1 min at 4 °C, resuspended in a final vol-
ume of 30 mL TBS (10 mM Tris–HCl, 100 mM NaCl,
1 mM MgCl2, 0.1 mM EDTA, pH 7. 4), and disrupted by
sonication (JP96-II, Shanghai, China) on ice 200 times
(on for 3 s, off for 6 s). The homogenate was centrifuged
at 12,000 rpm, 4 °C for 30 min. The supernatant was
collected, and 30 mL of chloroform was added and
mixed with the solution. The mixture was centrifuged at
12,000 rpm, 4 °C for 15 min, and the supernatant was
collected. The nanoparticles in the supernatant were












Restriction enzyme sites Nde I, Kpn I and Xho I are underlined; the cDNA sequence of LMWP is in boldface; pac site is in italic type
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analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS–PAGE) on 12 % gels. Then the
supernatant was incubated with DNase I (20 U/mL) and
RNase A (10 mg/mL) (Sigma, St Louis, MO) at 37 °C for
3 h, and purified by Bio-Gel A-1.5 m gel (Bio-Rad, USA)
filtration chromatography (BioLogic DuoFlow QuadTec
system, Bio-Rad, USA).
Western blotting
The purified products were verified by western blotting.
The purified VLPs was transferred from 12 % SDS-PAGE
gels onto a 0.45 μm polyvinylidene fluoride (PVDF) mem-
brane in the buffer containing 25 mM Tris-HCl (pH 8.3),
192 mM glycine, 20 % methanol, and blocked with 5 %
fat-free dry milk in phosphate-buffered saline (PBS) for
1 h. These membranes were incubated with anti-PP7 coat
protein (prepared using wild-type PP7 phage coat protein
as the immunogen by our lab) overnight at 4 °C and with
HRP-labeled secondary antibodies (Univ-bio, China) at
37 °C for 1 h in order. The signal was detected using the
Image Lab software (Bio-Rad, USA).
Transmission electron microscopy (TEM)
The recombinant PP7 VLPs were adsorbed on carbon-
coated glow-discharged copper grids for 2 min, and were
negatively stained with 2 % uranyl acetate for 2 min. The
VLPs were visualized using a Hitachi H7500 (Japan)
transmission electron microscope at a magnification of
100,000 × .
Nuclease resistant assay
The purified 2PP7 VLPs, 2PP7-Protamine VLPs and
2PP7-Protamine-GFP VLPs (800 μg/ml) were separately
mixed with DNase I (20 U/mL) and RNase A (10 mg/mL),
incubated at 37 °C for 12 h, and verified by 1 % agarose
gel electrophoresis.
Identification of nucleic acid packaged by PP7 capsids
using PCR
RNA isolation was performed using TRIzol (Thermo Fisher
Scientific, MA, USA) according to the manufacturer’s
instructions. To identify of the nucleic acid packaged by
2PP7-Protamine VLPs and 2PP7-Protamine-GFP VLPs,
respectively, ordinary PCR or reverse transcription-
polymerase chain reaction (RT-PCR) was performed with
the appropriate primers and templates at 94 °C for 5 min,
followed by 30 cycles of 10 s at 98 °C, 30 s at 60 °C, and
60 s at 72 °C, and followed by 7 min at 72 °C. 2PP7 gene
and GFP gene were amplified using primers PP7-for paired
with PP7-r and GFP-for paired with GFP-r, respectively.
The PCR products were verified by 1 % agarose gel electro-
phoresis with ethidium bromide staining, then purified and
ligated into the pMD18-T plasmid (Takara, Dalian, China)
for further verification by sequencing.
Cytotoxicity assay
Cos-7 cells (1 × 104/well) were incubated with various
concentrations of PP7 VLPs (0, 50, 100, 200, 400,
800 μg/mL) for 24 h or 48 h in triplicate. 10 μL CCK
(cell counting kit)-8 solution (Dojindo, Mashikimachi,
Kumamoto, Japan) was carefully added to each well 2 h
before detection. The absorbance of each well was mea-
sured at 450 nm with an ELISA plate reader (Multiskan
Go, Thermo, USA).
Cell penetrating assay
The 2PP7 VLPs and 2PP7-Protamine VLPs were fluores-
cently labeled with fluorescein isothiocyanate (FITC,
Sigma, St Louis, MO, USA), according to the manufac-
turer’s instructions. Briefly, 50 μL of 1 mg/mL FITC was
mixed with 950 μL of 2 mg/mL 2PP7 or 2PP7-Protamine
VLPs in a dialysis bag (MW: 3500, Union Carbide, USA).
The mixture was dialyzed in 0.1 M carbonate-bicarbonate
buffer (pH 9.0) at 4 °C in darkness for 12 h. After that, the
mixture was dialyzed in 2 L of PBS at 4 °C for 12 h. The
FITC-labeled 2PP7-Protamine VLPs were purified using
Sephacryl S-200 gel exclusion chromatography. Following
that, the purified VLPs were added to 1 × 106 RM-1 cells
per well with a final concentration of 10 μg/mL. Unlabeled
2PP7-Protamine VLPs and labeled 2PP7 VLPs were used
as negative controls. After 12 h of incubation, the cells
were washed three times with PBS to remove the VLPs-
containing medium. Intracellular distribution of the VLPs
was monitored under 200× magnification using a fluores-
cence microscope with an excitation filter BG12 and an
absorption filter OG4.
Thermal stability assay
The thermal stability of VLPs was determined by measur-
ing the fraction of proteins that remained soluble after
2 min at a given temperature [15]. 25 μL of VLP solutions
at a concentration of 1 mg/mL in TBS were added to pre-
heated tubes at 20, 30, 37, 40, 45, 50, 55, 60, 65, 70, 75, 80,
85, 90, 95, 100 °C. After 2 min, the tubes were transferred
into ice, where they remained for 8 min until they were
subjected to centrifugation at 18,000 g, 4 °C for 5 min in
microcentrifuge tubes. The supernatant fraction was then
transferred into fresh tubes. Using bicinchoninic acid
assay, the amount of proteins in the soluble fractions was
determined [31]. The values shown in Fig. 5d are the aver-
ages of three independent measurements.
Expression of packaged exogenous messenger RNA
(mRNA) in mammalian cell line
The 2PP7-Protamine-GFP VLPs (100 nM/mL) were
added to 3 × 104 RM-1 cells in 24-well plates in triplicate.
After 24 h, the expression of GFP protein was monitored
firstly by a fluorescence microscope. Then the cells were
stained with red fluorescent reactive dye (L23102, Life
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Invitrogen, USA) and DAPI (Beyotime, China) in order
before detection. The expression of GFP protein was
further monitored by confocal laser scanning microscopy
(LSM510 laser scanning microscope, Carl Zeiss,
Germany).
Quantitative real-time PCR (qPCR)
In a six-well plate, 1 × 105 cells/well was cultured. The
2PP7-TAT-23b or 2PP7-TAT-con VLPs (100nM) were
then added to each well and incubated with the cells for
24 h or 48 h at 37 °C. Total RNA was extracted from
the harvested cells with TRIzol. For GFP mRNA detec-
tion, the primers were designed on the base of these
sequences, as previously described (Table 1). The expres-
sion levels of GFP mRNA were quantified by real-time
PCR with the PrimeScript RT reagent Kit and SYBR
Premix Ex Taq™ II Kit (Takara, Dalian, China). Briefly,
approximately 50 ng of mRNA from each sample was
reverse-transcribed to cDNA with the GFP-qRT-r primer
and the GAPDH-r primer. Real-time PCR was then per-
formed on a StepOnePlusTM Real-Time PCR System. All
reactions were run in duplicate. In this study, GAPDH
mRNA was chosen as the internal control of GFP
mRNA. The relative expression levels of microRNAs
were calculated with the 2-⊿⊿Ct method [32], and the
differences in GFP mRNA concentrations between the
treated and control groups were expressed as fold
changes.
Statistical analysis
Statistical analyses were performed using the GraphPad
Prism Software (version 5.01). Data were considered statis-
tically significant when P < 0.05.
Additional file
Additional file 1: Figure S1. 2PP7-Protamine-GFP VLPs package the
mRNAs of GFP or PP7 coat protein carrying LMWP. The templates of PCR
in different lanes were as follows: lanes 1 and 6, purified VLPs sample;
lanes 2 and 5, RNA extracted from related VLPs; Lanes 3 and 4, reverse
transcription product of RNA extracted from related VLPs. M, DL 2000
DNA marker. Figure S2. The distribution of 2PP7-Protamine-GFP VLPs in
the RM-1 cells. The black arrow indicates the location of 2PP7-Protamine-
GFP VLPs. Figure S3. The sketch of structure of 2PP7-Protamine-GFP
VLPs. (DOC 632 kb)
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